Apolipoprotein A1 in Cerebrospinal Fluid and Plasma and Progression to Alzheimer’s Disease in Non-Demented Elderly
Open accessThe DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Abstract
Background: HDL-cholesterol transporter Apolipoprotein A1 (ApoA1) holds neuroprotective properties, such as inhibition of amyloid-β aggregation. Low plasma ApoA1 concentrations are associated with Alzheimer’s disease (AD). Little is known about ApoA1 levels in the pre-dementia stages of AD. Objective: To investigate associations between cerebrospinal fluid (CSF) and plasma ApoA1 levels and clinical progression toward AD in non-demented elderly. Methods: From the Amsterdam Dementia Cohort, we included 429 non-demented elderly with subjective cognitive decline (SCD; n = 206, 61±9 years, Mini-Mental State Exam (MMSE) 28±2) and mild cognitive impairment (MCI; n = 223, 67±8 years, MMSE 27±2), with a mean follow-up of 2.5±1.6 years. We used Cox proportional hazard models to investigate relations between CSF and plasma ApoA1 concentrations and clinical progression, defined as progression to MCI or AD for SCD, and progression to AD for MCI. Analyses were adjusted for age, gender, MMSE, and plasma cholesterol levels. Analyses were stratified for diagnosis and APOE ɛ4 carriership. Results: 117 patients (27%) showed clinical progression. One standard deviation increase of CSF ApoA1 was associated with a 30% increased risk of clinical progression (hazard ratio (HR) (95% CI) = 1.3(1.0–1.6)). The effect appeared to be attributable to the APOE ɛ4 carriers with SCD (HR 3.3(1.0–10.9)). Lower plasma ApoA1 levels were associated with an increased risk of clinical progression in APOE ɛ4 carriers with SCD (HR 5.0(1.3–18.9)). Conclusion: Higher CSF and lower plasma ApoA1 levels were associated with an increased risk of clinical progression in APOE ɛ4 carriers with SCD; suggesting that ApoA1 may be involved in the earliest stages of AD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jack, C. R., Knopman, D. S., Jagust, W. J., Petersen, R. C., Weiner, M. W., Aisen, P. S., Shaw, L. M., Vemuri, P., Wiste, H. J., Weigand, S. D., et al. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70291-0 · Cited by 4,396
Clinical and biomarker changes in dominantly inherited Alzheimer's disease
Bateman, R. J., Xiong, C., Benzinger, T. L. S., Fagan, A. M., Goate, A., Fox, N. C., Marcus, D. S., Cairns, N. J., Xie, X., Blazey, T. M., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1202753 · Cited by 3,814
Jessen, F., Amariglio, R. E., van Boxtel, M., Breteler, M., Ceccaldi, M., Chételat, G., Dubois, B., Dufouil, C., Ellis, K. A., van der Flier, W. M., et al. (2014) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2014.01.001 · Cited by 3,014 · cited 2×
“This entity has recently been suggested as a potential first symptomatic expression of AD [34, 35].”
Self-citationApolipoprotein E and its receptors in Alzheimer's disease: pathways, pathogenesis and therapy
Bu, G. (2009) · Nature Reviews Neuroscience · doi:10.1038/nrn2620 · Cited by 1,168
Cholesterol metabolism in the brain
Dietschy, J. M., & Turley, S. D. (2001) · Current Opinion in Lipidology · doi:10.1097/00041433-200104000-00003 · Cited by 906 · cited 2×
“ApoA1 is, next to ApoE, the second most abundant apolipoprotein in cerebrospinal fluid (CSF), present in HDL-like particles and maintaining cholesterol homeostasis in the brain [8–10].”
The overlap between vascular disease and Alzheimer’s disease - lessons from pathology
Attems, J., & Jellinger, K. A. (2014) · BMC Medicine · doi:10.1186/s12916-014-0206-2 · Cited by 739
DJ-1 and α-synuclein in human cerebrospinal fluid as biomarkers of Parkinson’s disease
Hong, Z., Shi, M., Chung, K. A., Quinn, J. F., Peskind, E. R., Galasko, D., Jankovic, J., Zabetian, C. P., Leverenz, J. B., Baird, G., et al. (2010) · Brain · doi:10.1093/brain/awq008 · Cited by 615
Jack, C. R., Wiste, H. J., Weigand, S. D., Rocca, W. A., Knopman, D. S., Mielke, M. M., Lowe, V. J., Senjem, M. L., Gunter, J. L., Preboske, G. M., et al. (2014) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70194-2 · Cited by 358
Apolipoproteins in human cerebrospinal fluid.
Roheim, P. S., Carey, M., Forte, T., & Vega, G. L. (1979) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.76.9.4646 · Cited by 282
Alzheimer's disease biomarker discovery using SOMAscan multiplexed protein technology
Sattlecker, M., Kiddle, S. J., Newhouse, S., Proitsi, P., Nelson, S., Williams, S., Johnston, C., Killick, R., Simmons, A., Westman, E., et al. (2014) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2013.09.016 · Cited by 223
Song, F., Poljak, A., Crawford, J., Kochan, N. A., Wen, W., Cameron, B., Lux, O., Brodaty, H., Mather, K., Smythe, G. A., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0034078 · Cited by 214
Koldamova, R. P., Lefterov, I. M., Lefterova, M. I., & Lazo, J. S. (2001) · Biochemistry · doi:10.1021/bi002186k · Cited by 131 · cited 4×
“ApoA1 has been shown to inhibit A (cid:2) aggregation and also to exert protective effects against A (cid:2) mediated neurotoxicity in vitro [15–17], as well as in animal models for AD [17, 19].”
InfluentialAPOE ε4 allele is associated with reduced cerebrospinal fluid levels of Aβ42
Prince, J. A., Zetterberg, H., Andreasen, N., Marcusson, J., & Blennow, K. (2004) · Neurology · doi:10.1212/01.wnl.0000128088.08695.05 · Cited by 128
Kawano, M., Kawakami, M., Otsuka, M., Yashima, H., Yaginuma, T., & Ueki, A. (1995) · Clinica Chimica Acta · doi:10.1016/0009-8981(95)06115-t · Cited by 68
Fagan, A. M., Christopher, E., Taylor, J. W., Parsadanian, M., Spinner, M., Watson, M., Fryer, J. D., Wahrle, S., Bales, K. R., Paul, S. M., et al. (2004) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)63399-8 · Cited by 54
Cited by
Amsterdam Dementia Cohort: Performing Research to Optimize Care
van der Flier, W. M., & Scheltens, P. (2018) · Journal of Alzheimer’s Disease · doi:10.3233/jad-170850 · Cited by 390
Self-citationEmerging role of HDL in brain cholesterol metabolism and neurodegenerative disorders
Turri, M., Marchi, C., Adorni, M. P., Calabresi, L., & Zimetti, F. (2022) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2022.159123 · Cited by 54
Zuin, M., Cervellati, C., Trentini, A., Passaro, A., Rosta, V., Zimetti, F., & Zuliani, G. (2021) · Diagnostics · doi:10.3390/diagnostics11060984 · Cited by 45
“found that lower plasma ApoA-I levels in 429 non-demented individuals are linked with increased risk of developing the disease [16].”
BackgroundLipid and lipoprotein metabolism in microglia: Alzheimer’s disease mechanisms and interventions
Sprenger, K. G., Lietzke, E. E., Melchior, J. T., & Bruce, K. D. (2025) · Journal of Lipid Research · doi:10.1016/j.jlr.2025.100872 · Cited by 42
Diminution of context association memory structure in subjects with subjective cognitive decline
Fan, L., Lai, Y., Chen, T., Hsu, Y., Chen, P., Huang, K., Cheng, T., Tseng, W. I., Hua, M., Chen, Y., et al. (2018) · Human Brain Mapping · doi:10.1002/hbm.24022 · Cited by 40
“…risk of developing AD dementia (Jessen et al., 2014) and mild cognitive impairment (MCI) (SargentCox, Cherbuin, Sachdev, & Anstey, 2011), and among those who were subjected to apolipoprotein epsilon 4 (ApoE4) genotyping (Slot et al., 2017), an increased risks of dementia conversion was also shown.”
Background
Metadata
- Authors
- Slot, R. E. R., Van Harten, A. C., Kester, M. I., Jongbloed, W., Bouwman, F. H., Teunissen, C. E., Scheltens, P., Veerhuis, R., & van der Flier, W. M.
- Venue
- Journal of Alzheimer’s Disease
- Publisher
- SAGE Publications
- Published
- 2016-12-30
- Volume
- 56
- Issue
- 2
- Pages
- 687-697
- ISSN
- 1387-2877 (ISSN-L)
- 1875-8908
- OpenAlex
- W2563243861
- Cited by
- 82
- References
- 15
- FWCI
- 6.47
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.